Chemomab Therapeutics Ltd.

Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.

CMMB | NDAQ

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: United States of America
Address:: KIRYAT ATIDIM, BUILDING 7, 6158002 TEL AVIV
Website:: https://www.chemomab.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet medical needs. The company's approach is centered on its discovery of the soluble protein CCL24 as a key driver of the vicious cycle of fibrosis and inflammation. Its lead product candidate, nebokitug (CM-101), is a first-in-class, dual-activity monoclonal antibody designed to bind to and neutralize CCL24. Nebokitug has demonstrated disease-modifying potential and a favorable safety profile in multiple clinical trials for severe fibrotic diseases. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial in primary sclerosing cholangitis (PSC), for which nebokitug has received FDA Fast Track and Orphan Drug designations.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Chemomab Therapeutics Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chemomab Therapeutics Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Chemomab Therapeutics Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Bayer AG A life science firm providing pharmaceuticals, consumer health, and crop science solutions.	Germany	BAY
Beam Therapeutics Inc. Developing precision genetic medicines using base editing to provide cures for serious diseases.	United States of America	BEAM
BELITE BIO, INC Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.	United States of America	BLTE
Benchmark Holdings Plc Aquaculture biotech providing nutrition and health solutions for sustainable farming.	United Kingdom	BMK
Benitec Biopharma Inc. Develops ddRNAi gene therapies to silence genes causing chronic, life-threatening diseases.	United States of America	BNTC
BeOne Medicines Ltd. Develops innovative and accessible cancer treatments for patients worldwide.	United States of America	ONC
BGM Group Ltd. A pharma holding co. making APIs & TCM derivatives via bio-fermentation and extraction.	United States of America	BGM
Bicara Therapeutics Inc. Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.	United States of America	BCAX
BICYCLE THERAPEUTICS PLC Developing novel bicyclic peptide medicines to precisely target hard-to-treat cancers.	United States of America	BCYC
BIFIDO. Co. Ltd Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.	South Korea	238200